SCHEMBL6771966

SCHEMBL6771966

COc1ccc(-c2ccc(S(=O)(=O)NC3CC(CNc4ccccc4)OC3=O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
NAAA Q02083 1/20 0.42
MMP2 P08253 6/20 0.42
MMP1 P03956 4/20 0.42
MMP3 P08254 4/20 0.42
MMP13 P45452 4/20 0.42
MMP7 P09237 2/20 0.42
MMP9 P14780 2/20 0.42
KCNA5 P22460 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PGR P06401 1/20 0.39
PTGER4 P35408 1/20 0.39
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768634 0.83 CA12 (0.43) ALDH1A1LMNAHPGDSMN1; SMN2CA12
SCHEMBL6768648 0.82 KCNA5 (0.43) ALDH1A1LMNAHPGDSMN1; SMN2CA12
SCHEMBL6771937 0.74 ALDH1A1 (0.46) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL6772307 0.74 ALDH1A1 (0.39) ALDH1A1LMNAHPGDSMN1; SMN2CA12
SCHEMBL6772860 0.72 MMP2 (0.39) ALDH1A1HPGDCA12CA9MMP2
SCHEMBL6773324 0.72 HSD11B1 (0.39) ALDH1A1LMNAHPGDSMN1; SMN2CA12
SCHEMBL8752437 0.65 PGR (0.78) ALDH1A1LMNASMN1; SMN2KDM4EPGR
SCHEMBL812663 0.64 PGR (0.82) ALDH1A1LMNASMN1; SMN2CA12CA1
SCHEMBL18780384 0.64 MAPT (0.46) ALDH1A1LMNAHPGDSMN1; SMN2CA1
SCHEMBL32679643 0.61 GAA (0.78) ALDH1A1LMNASMN1; SMN2KDM4EPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762198-B2 SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID THE PROCTER & GAMBLE COMPANY 2004-07-13 US disclosed
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-04 US disclosed
US-6566381-B1 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease THE PROCTER & GAMBLE COMPANY 2003-05-20 US disclosed
EP-1165530-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-01-02 EP disclosed
WO-2000051993-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors ADAM9, ADAM17, ADAM8 ALDH1A1 966/4885LMNA 2052/4885HPGD 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.